Charles River to Acquire HemaCare Corporation for $380M

 Charles River to Acquire HemaCare Corporation for $380M

Charles River to Acquire HemaCare Corporation for $380M

Shots:

  • Charles River to acquire HemaCare in all cash transactions at $25.40 /share, making a total deal value $380M with a premium of 33% to HemaCare’s volume-weighted average stock price over the last 60 trading days. The transaction is expected to be completed in Q1’20
  • The focus of the acquisition is to expand Charles River’s capabilities in the emerging, high-growth cell therapy market; to establish cell therapy solution from discovery via commercialization which will accelerate client retention and to provide a compelling value proposition for both clients and shareholders
  • The addition of HemaCare’s cell therapy products and services to Charles River’s integrated, early-stage solutions will form a unique, go-to partner for clients to work with Charles River across a cell therapy portfolio

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: HemaCare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post